Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
Drugs that sensitize tumour cells to ionizing radiation are prized because they can overcome resistance to radiotherapy. Here, the authors show that anti-tubulin drugs conjugated to cetuximab or trastuzumab can radiosensitize EGFR- or HER2-expressing tumors by increasing DNA damage and cell death du...
Enregistré dans:
Auteurs principaux: | Stephen R. Adams, Howard C. Yang, Elamprakash N. Savariar, Joe Aguilera, Jessica L. Crisp, Karra A. Jones, Michael A. Whitney, Scott M. Lippman, Ezra E. W. Cohen, Roger Y. Tsien, Sunil J. Advani |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/68ca94c8c46f45f584cf14bf29ee56ae |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
par: Moghbeli,Meysam, et autres
Publié: (2019) -
Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors.
par: Yoon Sin Oh, et autres
Publié: (2011) -
Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.
par: Jinming Gu, et autres
Publié: (2014) -
Increased NRG1-ErbB4 signaling in human symptomatic epilepsy
par: Jun-Ming Zhu, et autres
Publié: (2017) -
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.
par: Gillian Farnie, et autres
Publié: (2013)